IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy
Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.
EP: 1.Overview of SCLC and Importance of Early Diagnosis
EP: 2.Use of the TNM Staging System in SCLC
EP: 3.Progress in the Treatment and Management of SCLC
EP: 4.Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases
EP: 5.Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy
EP: 6.Management of Adverse Events Associated with Durvalumab + Chemotherapy
Now Viewing
EP: 7.IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy
EP: 8.Ongoing Trials and Real-World Studies in Frontline SCLC
EP: 9.Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy
EP: 10.Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy
EP: 11.Lurbinectedin for SCLC Treatment in the Second-Line Setting
EP: 12.Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting
EP: 13.Choosing the Appropriate Treatment in the Second Line Setting in SCLC
EP: 14.Investigational Agents in SCLC in the Second Line Setting and Beyond
EP: 15.Clinical Practice Pearls and the Future of SCLC
Related Videos
Related Content
